Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Striatal uptake of a novel PET ligand, [F-18]beta-CFT, is reduced in earlyParkinson's disease
Autore:
Rinne, JO; Bergman, J; Ruottinen, H; Haaparanta, M; Eronen, E; Oikonen, V; Sonninen, P; Solin, O;
Indirizzi:
Univ Turku, Dept Neurol, FIN-20520 Turku, Finland Univ Turku Turku Finland FIN-20520 Dept Neurol, FIN-20520 Turku, Finland Univ Turku, Dept Radiol, FIN-20520 Turku, Finland Univ Turku Turku Finland FIN-20520 Dept Radiol, FIN-20520 Turku, Finland Accelerator Lab, Turku, Finland Accelerator Lab Turku FinlandAccelerator Lab, Turku, Finland Med PET, Turku, Finland Med PET Turku FinlandMed PET, Turku, Finland Univ Turku, Cent Hosp, Turku PET Ctr, FIN-20520 Turku, Finland Univ TurkuTurku Finland FIN-20520 rku PET Ctr, FIN-20520 Turku, Finland
Titolo Testata:
SYNAPSE
fascicolo: 2, volume: 31, anno: 1999,
pagine: 119 - 124
SICI:
0887-4476(199902)31:2<119:SUOANP>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; DOPAMINE UPTAKE SITES; SUBSTANTIA-NIGRA; TRANSPORTER; BRAIN; BINDING; INVIVO; C-11-NOMIFENSINE; DEMENTIA; SYSTEM;
Keywords:
CFT; dopamine; dopamine reuptake; Parkinson's disease; PET; positron emission tomography;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Rinne, JO Univ Turku, Dept Neurol, FIN-20520 Turku, Finland Univ Turku Turku Finland FIN-20520 l, FIN-20520 Turku, Finland
Citazione:
J.O. Rinne et al., "Striatal uptake of a novel PET ligand, [F-18]beta-CFT, is reduced in earlyParkinson's disease", SYNAPSE, 31(2), 1999, pp. 119-124

Abstract

[F-18]beta-CFT is a novel PET ligand for dopamine reuptake sites. In this study, [F-18]beta-CFT uptake was studied in nine patients with early Parkinson's disease (PD) without antiparkinsonian medication and in six age-matched controls. The uptake of [F-18]beta-CFT was calculated as a (region-cerebellum)/cerebellum ratio at 150-210 min after injection. The mean uptake in the putamen contralateral to the predominant symptoms (1.04 +/- 0.40, mean /- SD; P < 0.001) was reduced to 31% of the mean control value. In the "ipsilateral" putamen, the ratio in PD patients (1.50 +/- 0.50, P < 0.001) wasreduced to 45% of the control mean (3.33 +/- 0.61). Individually, all PD patients had [F-18]beta-CFT uptake values below 2 SD from the control mean in the contralateral putamen. The decline in [F-18]beta-CFT uptake in the caudate nucleus was milder than that seen in the putamen. The uptake was reduced contralaterally (2.19 +/- 0.47, P < 0.01) to 67% and ipsilaterally (2.49 +/- 0.54, P < 0.05) to 77% of the control mean (3.17 +/- 0.61). In the medial frontal cortex or dorsolateral prefrontal cortex, no significant difference in [F-18]beta-CFT uptake between patients and controls was seen. In conclusion, [F-18]beta-CFT is a powerful ligand to demonstrate presynaptic dopaminergic defect in PD and shows a clear separation of patient and control values. Synapse 31:119-124, 1999. (C) 1999 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 14:31:33